NYSE:VNRX
VOLITIONRX LTD Stock News
$0.770
-0.0300 (-3.75%)
At Close: May 17, 2024
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q2 2022 Results - Earnings Call Transcript
03:10pm, Saturday, 13'th Aug 2022
VolitionRx Limited (NYSE:VNRX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - CEO Dr. Tom Butera - CEO, Volition Veterinary Teri
VolitionRx ends 2Q with $16.7M, secures further funding to advance trials and commercialization efforts
05:01pm, Wednesday, 10'th Aug 2022
VolitionRx (NYSE-A:VNRX) Limited ended the second quarter with $16.7 million in the bank to help advance research and commercialization efforts for its Nucleosomics platform for blood tests. The Hende
VolitionRx to participate in US clinical study for NETs in sepsis cancer patients
09:25am, Wednesday, 10'th Aug 2022
VolitionRx (NYSE-A:VNRX) Limited has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (NETs) in
VolitionRx appoints DXOCRO to undertake development and clinical validation studies for its Nu.Q product portfolio in the US
09:44am, Monday, 08'th Aug 2022
VolitionRx (NYSE-A:VNRX) Limited said it has appointed Diagnostic Oncology CRO, LLC (DXOCRO) to undertake development and clinical validation studies for its Nu.Q product portfolio in the US. The dia
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to t
VolitionRx announces pricing of underwritten public offering of 3 million shares at a public offering price of $2.00 each
08:57am, Friday, 29'th Jul 2022
VolitionRx (NYSE-A:VNRX) Limited has announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross procee
VolitionRx presents data related to its NETs research at ISTH Congress
10:30am, Wednesday, 13'th Jul 2022
VolitionRx (NYSE-A:VNRX) Limited announced it had presented data about its work on neutrophil extracellular traps, or NETs, at the International Society on Thrombosis and Haemostasis (ISTH) Congress.
VolitionRx says Nu.Q NETs test gets CE mark enabling clinical use in over 27 countries across Europe
10:16am, Tuesday, 31'st May 2022
VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in over 27 countries across Europe. NETosis is a unique f
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q1 2022 Results - Earnings Call Transcript
04:09pm, Thursday, 12'th May 2022
VolitionRx Limited (NYSE:VNRX ) Q1 2022 Results Conference Call May 12, 2022 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President
VolitionRx reports strong 1Q anchored by $10M milestone payment from Heska for Nu.Q Vet Cancer Screening Test
05:03pm, Wednesday, 11'th May 2022
VolitionRx (NYSE-A:VNRX) Limited rounded out a strong first quarter by receiving a $10 million milestone payment from Heska Corporation for the company's Nu.Q Vet Cancer Screening Test. In exchange fo
VolitionRx launches its Nu.Q Vet Cancer Test in Asia through distributor SAGE Healthcare
09:48am, Monday, 25'th Apr 2022
VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q Vet Cancer Test has been launched in Asia through SAGE Healthcare Private Limited, which was appointed as a non-exclusive licensee and distributor for th
VolitionRx appoints industry veteran Sharon Ballesteros as its US head of quality and development process
09:45am, Wednesday, 06'th Apr 2022
VolitionRx (NYSE-A:VNRX) Limited has announced the appointment of Sharon Ballesteros as the company's new US head of quality and development process. VolitionRx (NYSE-A:VNRX) said Ballesteros has m
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call Transcript
12:04pm, Thursday, 31'st Mar 2022
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call Transcript
VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening test
10:34am, Tuesday, 29'th Mar 2022
VolitionRx (NYSE-A:VNRX) Ltd has struck an exclusive $28 million deal with veterinary diagnostic firm Heska Corporation to license and sell the former's Nu.Q vet cancer screening test at the point-of
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
04:25pm, Monday, 28'th Mar 2022
Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will